Diagnosis of salivary gland tumours (SGTs) pose a challenge even to the experienced pathologist and immunohistochemistry may be a useful adjunct. Aim of this study is to assess the degree of differential expression of α-SMA among salivary gland tumours, and to evaluate the possible diagnostic benefits. Sections of formalin-fixed, paraffin embedded tissues blocks obtained from SGTs were stained using α-SMA monoclonal antibody. Immunoreactivity were scored based on Regezi method, with 0 indicating nonreactive, 1+ representing scattered spotty staining, 2+ indicating up to 25% of tumour cells positive, 3+ indicating between 25% to 50% tumour cells positive, and 4+ indicating more than 50%. Scores of 1+ and 2+ were regarded as low reactivity, 3+ was regarded as moderate reactivity, and 4+ was regarded as high reactivity. Data was analyzed and p-value <0.05 was regarded as significant. Out of the 42 cases of SGTs studied, 33 (78.6%) expressed α-SMA. The highest α-SMA score observed in adenoid cystic carcinoma, pleomorphic adenoma and basal cell adenoma was 4+, followed by peak score of 3+ observed in polymorphous adenocarcinoma, while 2+ was the highest score in mucoepidermoid carcinoma and epimyoepithelial carcinoma. Acinic cell carcinoma did not express α-SMA in all cases studied. There was significant differential expression of α-SMA between acinic cell carcinoma and adenoid cystic carcinoma (p=0.009); mucoepidermoid carcinoma and pleomorphic adenoma (p=0.048); mucoepidermoid and adenoid cystic carcinoma (p=0.004). In conclusion, α-SMA may be useful in the exclusion of acinic cell carcinoma and in the differential diagnosis between pleomorphic adenoma and mucoepidermoid carcinoma.